Skip to content

EXOZ EXOZ Additional Paid-In Capital

Additional Paid-In Capital at other companies

Gevo logo
GevoGEVO
$1.3B+0.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$6.67B+1.5%
NAG
Niagen Bioscience, Inc. Common StockNAGE
$240.46M+3.6%
Opko Health logo
Opko HealthOPK
$3.57B+2.5%
Upexi logo
UpexiUPXI
$230.15M+315%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$0-100%

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's additional paid-in capital?
EXOZ (EXOZ) reported additional paid-in capital of $25M in Q1 2026.
How has EXOZ's additional paid-in capital changed year-over-year?
EXOZ's additional paid-in capital increased by 10.2% year-over-year, from $22.68M to $25M.
What is the long-term trend for EXOZ's additional paid-in capital?
Over 2 years (2023 to 2025), EXOZ's additional paid-in capital has grown at a 107.3% compound annual growth rate (CAGR), from $5.7M to $24.5M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.